Skip to main content Back to Top
Advertisement

2/24/2017

Epinephrine Injection

Products Affected - Description

    • Epinephrine injection, Pfizer, 0.1 mg/mL, Abboject 18 gauge glass syringe, 10 count, NDC 00409-4901-18

Reason for the Shortage

    • American Regent discontinued both epinephrine presentations in early 2015.
    • Amphastar has epinephrine available.
    • BPI Labs has epinephrine available.
    • Pfizer has discontinued epinephrine Abboject syringes.
    • Par has Adrenalin available.

Available Products

    • Adrenalin injection, Par Sterile Products, 1 mg/mL, 1 mL vial, 25 count, NDC 42023-0159-25
    • Adrenalin injection, Par Sterile Products, 1 mg/mL, 30 mL multiple dose vial, 1 count, NDC 42023-0168-01
    • Epinephrine injection, Amphastar, 0.1 mg/mL, 10 mL syringe, 10 count, NDC 76329-3316-01
    • Epinephrine injection, Amphastar, 1 mg/mL, 30 mL vial, 1 count, NDC 76329-9061-00
    • Epinephrine injection, BPI Labs, 1 mg/mL, 2 mL containing 1 mL sulfite-free and preservative-free ampule, 10 count, NDC 54288-0103-10
    • Epinephrine injection, Pfizer, 0.1 mg/mL, 10 mL 20 gauge LifeShield syringe, 10 count, NDC 00409-4921-34
    • Epinephrine injection, Pfizer, 1 mg/mL, 1 mL ampule, 25 count, NDC 00409-7241-01

Estimated Resupply Dates

    • All marketed presentations are available.

Implications for Patient Care

    • Epinephrine products from Amphastar and Pfizer are not FDA approved. BPI Lab's epinephrine injection is labeled to increase mean arterial blood pressure in patients with hypotension associated with septic shock, emergency treatment of allergic reactions including anaphylaxis, and induction and maintenance of mydriasis during intraocular surgery. Par's Adrenalin is labeled for emergency treatment of anaphylaxis and induction.
    • Adrenalin injection vials from Par Sterile Products contain 1 mg/mL sodium metabisulfite. Pfizer's epinephrine ampules contain 0.9 mg/mL sodium metabisulfite.
    • BPI Lab's epinephrine injection is preservative free and sulfite-free.

Updated

Updated February 24, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 3, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins